The science of immunotoxicology began in the early 1970s, following the recognition of increased sensitivity to infection following exposure of test species, including monkeys, hamsters, ducks, rats, mice and guinea pigs to various xenobiotics. Reduced resistance to infectious disease was a well-documented consequence of primary and acquired immunodeficiencies, but a novel outcome of xenobiotic exposure, leading some to characterize xenobiotic-induced immunosuppression as "chemical AIDS". Although the comparison was scientifically inappropriate, "immunotoxicity" was often thought of as synonymous with "immunosuppression" during the formative years of the discipline, although hypersensitivity, allergy, and autoimmunity were recognized as potential exposure outcomes.
need access to PBMCs; it provides answers to questions regarding the toxicity of potential new drug compounds on humans specially on their immune system. Drug toxicity that affects PBMCs can cause a variety of serious, even life-threatening, toxic side effects, including suppression and toxicity of immune system. PBMCs are also critical tools for predictive studies determining the dosage limit of new drug compounds.
2) Side-by-side comparison studies;researchers typically need both normal PBMCs and diseased PBMCs to compare in side-by-side studies, to get to the molecular heart of a specific toxic response. Understanding which pathways or molecules are impacted helps drug research proceed more rapidly, with greater efficaciousness and low immuntoxicity.
3) Occupational exposure research;Job and/or environmental exposures to toxic compounds such as heavy metals or benzene can have extremely deleterious effects on immune system. For example, benzene is known to affect stem and progenitor cells in bone marrow.Research has shown that immunotoxicity occurs in people exposed to significant levels of benzene. 4) Chemotherapy toxicity impact studies;Studies of patients suffering from non-Hodgkin's lymphoma, breast cancer and non-small cell lung cancer (NSCLC) have concluded that older individuals tend to exhibit greater toxicity after receiving cytotoxic chemotherapy compounds, as compared to younger patients. Studies have continued to explore this causal association between age and PBMCs toxicity. The study concluded that, contrary to prevailing views, older NSCLC patients do not show a greater PBMCs suppression when compared to younger patients after chemotherapy treatment for NSCLC. 5) Personalized medicine/pharmacogenomics;as the field of individualized drug therapy advances, a better understanding of the "why" behind individual variation in drug response becomes increasingly important.Recent studiesfocus on the genetic variations of drug target, metabolism, transport, and safety. The ultimate goal of such studies is to be able to introduce new medications that are both safe and effective for specific genetic profiles. Because PBMCs are common targets for toxic reactions, it is an important tool for researchers exploring the new and exciting horizons of pharmacogenomics. 
Dr. Jalal Pourahmad is currently working as full professor at the

